Novartis, a pharmaceuticals company, and the National Football League have announced an unprecedented partnership that names Novartis as the official first-in-category corporate pharmaceutical partner ...

A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...

Novartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football ...

The NFL have signed its first-ever pharmaceutical partner in a multi-year deal with Novartis to focus on the NFL’s health ...

The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based ...

Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...

The NFL has inked a multi-year deal with pharmaceutical giant Novartis, marking its first such partnership. This ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

Novartis AG (NYSE:NVS – Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 54,767 call options on the stock. This represents an increase of 2,389% ...

High-dose vitamin D supplementation reduces disease activity in clinically isolated syndrome typical of MS, results of a ...

Novartis shareholders elected Giovanni Caforio as new member and Chair of the Board of Directors as well as Elizabeth McNally as new member of the Board of Directors. Joerg Reinhardt, Charles L.